After two years on top of Australian patent filing charts – including a remarkable (by Australian standards) 435 applications in 2020 – Chinese telecommunications manufacturer OPPO dropped back to third position in 2021. The top spot was taken by last year’s runner-up, South Korea’s LG Electronics, which filed 251 new Australian standard patent applications, up from 236 in 2020. China’s Huawei Technologies took second place, with 243 new applications, also increasing its filings, up from 229 in 2020. Huawei now owns nearly 1,300 live Australian patents and applications, which is a significant investment for a company that is effectively barred from the Australian market. It is likely, however, that many of these patents and applications cover standardised mobile and data communications technologies that are implemented across the industry, and which therefore provide Huawei with a substantial stream of licensing income.
The top Australian resident applicant, once again, was electronic gaming system developer Aristocrat Technologies. However, from a peak of 252 applications filed in 2018, Aristocrat’s filings have declined significantly. It filed only 72 new standard patent applications in 2021, falling to equal 21st place in the annual ranking (alongside the University of Texas System). Over the same period, Aristocrat has been engaged in a Federal Court battle with the Australian Patent Office in an effort to establish the patent-eligibility of many of its gaming-related inventions, recently suffering a setback in the form of a loss on appeal to a Full Bench of the Court.
The leading antipodean applicant is now New Zealand’s Fisher & Paykel Healthcare (which is separate these days from the well-known maker of home appliances). Fisher & Paykel Healthcare filed 127 Australian standard patent applications in 2021, up from 94 the previous year, to take 7th place in the rankings. Ironically, the leading filer of New Zealand patent applications in 2021 was Australian medical device manufacturer Resmed, with 142 filings, while Fisher & Paykel Healthcare appears to have no interest in patent protection in its domestic market. Meanwhile, Resmed followed the opposite trans-Tasman strategy, filing just 25 applications in its home market of Australia.
No other Australian (or New Zealand) applicant appeared in the top 30 filers for 2021. The next highest Australian applicant, after Aristocrat, was the Commonwealth Scientific and Industrial Research Organisation (CSIRO), with 48 applications, followed by NewSouth Innovations (the University of New South Wales’ commercialisation arm) on 29. The Australian top five was rounded out by Breville (26) and Resmed (25).
The top three filers of provisional applications were CSIRO (56), Resmed (51), and NewSouth Innovations (47).
Innovation patent filings were dominated, in the final few months of full operation of the system, by Chinese and Indian applicants, of which the top two were China’s Qingdao Agricultural University, and the delightfully-named Lovely Professional University in India. The leading ‘credible’ filers of innovation patent applications in 2021 were US-based Calerpillar Inc (31 filings), agricultural chemical developer Imtrade Australia (26 filings), and Australian radio technology company Benelec (14 filings).
Read on for full tables of the leading filers for each application type.
VANCOUVER, BC – Trait Biosciences Inc., a leading cannabinoid biotechnology research organization, announced that it has successfully completed key scientific studies and operational milestones associated with its Series A Financing, […]